NCT02953782
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations:
Breast Cancer Tissue:
Recruitment Status: Recruiting
Phase 1|Phase 2
Drug Category: Therapeutic Antibody, Immunotherapy
Key Eligibility Criteria:
Gender: All
Age: 18 Years and older (Adult, Senior)
Location of Metastases:
Additional Notes: Breast cancer patients are only eligible for Phase 1b
Exclusions: Active brain metastases
https://ClinicalTrials.gov/show/NCT02953782